<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02290548</url>
  </required_header>
  <id_info>
    <org_study_id>14MMHIS164</org_study_id>
    <nct_id>NCT02290548</nct_id>
  </id_info>
  <brief_title>Effect of High-flow Nasal Oxygen on Extubation Outcome</brief_title>
  <official_title>Effect of High-flow Nasal Oxygen vs Standard Oxygen Therapy on Extubation Outcome With High Risk of Extubation Failure in Medical ICU Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mackay Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mackay Memorial Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether high flow nasal cannula is effective in
      lowering the reintubation rate after extubation for high risk patients in medical intensive
      care unit
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study hypothesis is that Optiflow may reduce the extubation failure rate for high risk
      patients in medical intensive care unit.In the intervention group, patients fulfilling
      inclusion criteria and not presenting any of the exclusion criteria will receive high-flow
      nasal cannula (Optiflow Airvo2, Fisher &amp; Paykel Healthcare Ltd., New Zealand) after
      extubation. The oxygen concentration (FiO2) will be set to reach an oxygenation target
      similar to control patients (see below), while the gas flow rate will be set at 50 L/min.In
      the control group, patients fulfilling inclusion criteria and not presenting any of the
      exclusion criteria will receive standard oxygen therapy including nasal cannula or oxygen
      mask after extubation. The FiO2 will be set to obtain a arterial oxygen saturation (SpO2)
      between 92% and 98% (or between 88% and 95% in hypercapnic patients). NIPPV or intubation
      will be applied in both group if respiratory distress noted. High flow nasal cannula will be
      tried before NIPPV or intubation in the control group patients.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>reintubation rate</measure>
    <time_frame>72 hours after extubation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Non-Invasive Ventilation</measure>
    <time_frame>at day 28 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU readmission rate due to respiratory failure</measure>
    <time_frame>at day 28 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality rate</measure>
    <time_frame>at day 28 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>at day 28 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>at day 28 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>at day 28 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nosocomial pneumonia rate</measure>
    <time_frame>at day 28 after inclusion in the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Desaturation ( SaO2&lt; 90%)</measure>
    <time_frame>72 hours after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe hypoxemia (PaO2/Fraction of inspired O2 &lt; 200)</measure>
    <time_frame>Time Frame: 72 hours after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hypercapnia (PaCO2 &gt; 50)</measure>
    <time_frame>72 hours after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory acidosis (arterial pH &lt; 7.30)</measure>
    <time_frame>72 hours after extubation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>severe tachypnea (&gt;40/min)</measure>
    <time_frame>72 hours after extubation</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Respiratory Failure</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>high flow nasal cannula</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High flow nasal cannula immediately use after extubation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>stanrd oxygen therapy</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oxygen cannula or mask after extubation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>high flow nasal cannula</intervention_name>
    <description>High flow nasal cannula used in postextubation patients</description>
    <arm_group_label>high flow nasal cannula</arm_group_label>
    <arm_group_label>stanrd oxygen therapy</arm_group_label>
    <other_name>Optiflow Airvo2 (Fisher &amp; Paykel Healthcare)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients mechanically ventilated for &gt; 48 hours and at least one of the following:

          -  &gt; 65 y/o

          -  Cardiac failure as the primary indication of mechanical ventilation

          -  COPD

          -  Bronchiectasis

          -  Old pulmonary tuberculosis with destructive lung

          -  Chronic renal failure

          -  Neuromuscular disease

          -  BMI &gt; 30

          -  Inability to manage respiratory secretions

          -  ARDS

        Exclusion Criteria:

          -  Presence of tracheostomy

          -  Recent facial trauma

          -  Active gastro-intestinal bleeding

          -  Planned NIPPV support after extubation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kuo Li Kuo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>+886975835135 lmn4093@gmail.com</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kuo li Kuo, MD</last_name>
    <phone>+886975835135</phone>
    <email>lmn4093@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mackay Memorial Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Kuo Li Kuo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2014</study_first_submitted>
  <study_first_submitted_qc>November 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 14, 2014</study_first_posted>
  <last_update_submitted>December 11, 2014</last_update_submitted>
  <last_update_submitted_qc>December 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 15, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>high flow nasal cannula</keyword>
  <keyword>extubation failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

